BTCC / BTCC Square / Global Cryptocurrency /
Novo Nordisk Stock Plunges as Legal Threat Looms Over $49 Wegovy Copycat

Novo Nordisk Stock Plunges as Legal Threat Looms Over $49 Wegovy Copycat

Published:
2026-02-06 09:09:02
18
2
BTCCSquare news:

Novo Nordisk shares tumbled 7% after Hims & Hers unveiled a compounded version of Wegovy priced at $49, dramatically undercutting the pharmaceutical giant's $149 offering. The Danish company swiftly threatened legal action, labeling the MOVE as "illegal mass compounding" that jeopardizes patient safety.

Eli Lilly shares mirrored the decline, dropping 7% on heightened competition fears in the weight-loss drug market. Hims & Hers defends its product as personalized compounding, claiming a distinct formulation sidesteps semaglutide patents valid until 2032.

The controversy compounds Novo Nordisk's struggles, with the stock having lost 50% of its value in 2025 and declining another 15% in 2026 amid projected sales drops of up to 13% this year. Market watchers anticipate protracted legal battles that could reshape pricing dynamics in the lucrative weight-loss pharmaceutical sector.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.